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Abstract
A 70-year-old gentleman underwent prostatectomy for bladder outlet obstruction due to enlarged prostate and was 
found to have primary extragastrointestinal stromal tumour (EGIST). He has been started on imatinib therapy and is 
presently on follow-up. Prostatic EGIST should be one of the differential diagnoses in patients with enlarged prostate 
with normal prostate-specific antigen levels.
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Introduction
Gastrointestinal stromal tumours (GIST) are common in 
the digestive tract. They have their origin in the pacemaker 
cells specific to the GI tract. Since similar cells are known 
to exist in the prostate, such tumours can very rarely be 
found to arise from this site also. They can be recognised 
based on histology using specific immunohistochemical 
stains and can be treated by immunotherapy, surgery or 
combination of the two methods.[1,2] In this case report, a 
primary prostatic extra-GIST (EGIST) is presented, which 
has been treated with imatinib (IM) and is considered for 
surgery.
Case Report
A 70-year-old male patient had undergone transvesical 
prostatectomy in September 2017, for complaints of 
severe lower urinary tract symptoms i.e., hesitancy, 
poor stream and sense of incomplete voiding for the 
past 5 months. As per patient’s record pre-operative 
examination revealed an enlarged firm nodular prostate. 
His pre-operative prostate-specific antigen (PSA) level 
was 2.67 ng/ml.
Histopathologic examination of specimen from revealed 
features consistent with GIST.
Immunohistochemical staining showed the following 
reactivity:
• CD117 diffuse positive.




He was further worked up with colonoscopy and upper 
GI endoscopy to find any primary tumour in the lower 
GI tract. No gross abnormality was found on these 
examinations.
He was accepted in Shaukat Khanum Memorial Cancer 
Hospital and Research Centre through walk-in clinic 
and presented to the Department of Uro-oncology. 
Histopathology was reviewed at our institution as per 
policy. It showed that on gross examination, there were 
multiple irregular fragments of greyish-brown tissue, 
measuring 11.0 cm × 10.0 cm × 5.0 cm. On sectioning, 
greyish-brown and haemorrhagic tissue was noted. The 
whole specimen was submitted in three blocks.
Microscopic examination shows neoplastic lesion, which 
was composed of fascicles of spindle cells. These neoplastic 
cells contain a moderate amount of eosinophilic cytoplasm 
with oval-to-elongated nuclei and inconspicuous nucleoli. 
At places, cytoplasmic vacuolisation is also appreciable. 
The mitotic count was 2–3/50 high-power fields (HPF) 
[Figure 1]. No normal prostatic tissue was seen.
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Immunohistochemical staining with CD117 and DOG1 
and the specimen showed strong positivity. CD117 
showed diffuse cytoplasmic staining in tumour. DOG1 
showed diffuse cytoplasmic and membranous staining in 
tumour cells. Details of immunohistochemical staining 
are as follows:
• DOG1: Clone (SP31).
• Performed on Ventana BenchMark XT.
• CD117: Clone T595.
• Performed on Bond Leica 3.
His chest and abdominal computed tomography (CT) 
was also reviewed which was unremarkable. Review of 
pelvic magnetic resonance imaging (MRI) [Figure 2] 
scan showed a significantly enlarge residual prostate, 
but no abnormality could be identified in the rectum. 
Furthermore, the prostate was completely separated from 
the rectum excluding the possibility of a rectal GIST that 
may be involving the prostate.
Pathological diagnosis was GIST based on the histology 
and immunostaining. Since no other primary site could 
be identified on endoscopy and imaging, it was concluded 
to be a case of primary prostatic EGIST, and as on 
histopathology, there are no differences between GISTs 
from GI or prostatic origins.
The case was presented in the Multidisciplinary Team 
Meeting and it was discussed that, based on the large size 
of the residual prostate and its proximity to the rectum, 
complete surgical excision may not be possible, and there 
is a risk of rectal injury. The treatment plan was discussed 
with the patient and he was referred to the medical 
oncologist and started on imitanib mesylate, a selective 
protein tyrosine kinase inhibitor at the dose of 400 mg 
once daily to see the response. Follow-up CT [Figure 3] 
scan has been performed before the commencement of 
IM therapy which showed enlarged prostate without 
contiguous visceral involvement and local or distant 
metastasis.
The patient has taken imitanib mesylate for almost 
6 months now. Repeat MRI pelvis done on 29 May 2018 
showed a small focus of nodular enhancement interposed 
Figure 2: Biopsy (×40 images) shows a collection of bland 
spindle cells in the form of short intersecting fascicles showing 
eosinophilic fibrillar cytoplasm. Perinuclear cytoplasmic 
vacuoles and minimal pleomorphism are seen
Figure 1: Magnetic resonance imaging (T2W sequence): 
Significant residual prostate is noted
Figure 3: Computerised tomographic scan showing enlarge 
prostate without any local visceral or nodal involvement
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between the lower rectums and the prostate is suggestive 
of residual tumour [Figure 4]. The case was again 
discussed in multidisciplinary team, and it was noted that 
as there has been no response to imitanib mesylate over 
the period and the risk of incomplete resection and rectal 
injury remains, it will be discussed with GI surgeon for 
combined radical prostatectomy and proctectomy with 
temporary or permanent colostomy. In the meanwhile, 
the dose of imitanib mesylate has been increased to 
600 mg a day.
Discussion
GIST is a tumour of mesenchymal origin from the GI tract. 
The EGISTs have similarities with their GI counterparts 
in their histological and immunohistochemical 
characteristics, but they have little or no connection with 
the adjacent serosal surfaces of the GI tract. These EGISTs 
constitute 5–10% of such stromal tumours and patients 
have a mean age of 58 years.[3-7]
Van Der Aa et al. reported the first case of prostatic 
EGIST.[5] Prostate is also the very rare site of the origin of 
other mesenchymal malignancies. These include sarcomas 
which account for approximately 0.1%–0.2%, including 
leiomyosarcomas and rhabdomyosarcomas.
Other primary sarcomas are extremely uncommon, 
which also include primary prostatic EGIST along 
with malignant fibrous histiocytoma, angiosarcoma, 
osteosarcoma, chondrosarcoma, malignant peripheral 
nerve sheath tumour and synovial sarcoma.[9] Due to the 
proximity of prostate with the rectum, the possibility of 
patients presenting with urinary symptoms from large 
GIST of rectal origin (due to large volume causing mass 
effect) should be excluded.
Table 1 presents the previously reported cases of EGIST 
including the present case. Patients commonly present 
with burning micturition, urinary frequency, haematuria, 
and pelvic or perineal pain. They mostly remain clinically 
silent in the initial stages and attain large size. Physical 
examination and imaging often reveal a significantly 
enlarged prostate. PSA level is almost always within the 
normal range 1. If resectable, surgery is the definitive 
treatment option in patients with prostatic EGISTs.[10,11]
If possible, complete en bloc removal of the tumour 
and the surrounding organs that are involved should be 
performed. Conventional chemotherapy and radiotherapy 
are not effective in the treatment of EGISTs. IM, which is 
Figure 4: Follow-up magnetic resonance imaging shows a new 
contrast-enhancing nodule (arrow)
Table 1: Reported cases of prostatic extra gastrointestinal stromal tumours
Reference Age (years) T‑size (cm) Treatment
Van der Aa et al., 2005[5] 49 14.2 Imatinib
Lee et al., 2006[4] 75 6.7 TURP+RP
Yinghao et al., 2007[10] 49 8 RP
Ou et al., 2013[9] 39 10 RP+Imatinib
Zhang et al., 2014[3] 31 6.5 Imatinib
Liu et al., 2014[1] 55 10.5 RP+Imatinib
Etit et al., 2017[8] 56 6 Enucleation
Present case 70 5 Imatinib
TURP: Transurethral resection of prostate, RP: Radical prostatectomy
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a tyrosine kinase inhibitor, is used as methods of adjuvant 
therapy. It also has a role in the treatment of advanced, 
unresectable, and metastatic GIST. Fletcher et al. proposed 
the first risk classification system for GIST in 2002, which 
is termed as ‘NIH classification’. Its goal was to develop a 
consensus approach to diagnose and help in morphologic 
prognostication of GISTs. The criteria so developed were 
based on tumour size and mitotic count [Table 2]. Similar 
predictive value was also proposed by Reith et al., for 
EGISTs in his analysis of 48 patients, according to whom 
mitotic activity and necrosis have independent predictive 
value.[7]
Several other workers evaluated the NIH classification 
and proposed subsequent prognostic schemes for GISTs, 
including other variables such as the anatomic site, 
because prognosis of GISTs from gastric and non-gastric 
origins was noted to be different. The other two widely 
used classification systems include the NCCN risk 
classification for GIST, based on the work of Miettinen 
and Lasota in 2006,[12] and the American Joint Committee 
on Cancer prognostic scheme.
Due to the scarcity of data on the primary prostatic 
EGISTs, the implementation of classification schemes 
for GISTs on these tumours has not been validated. In 
the present case, the relatively small size (5 cm), low 
mitotic counts (2–3/50 HPFs) and absence of necrosis 
were the low features. Therefore, it was decided to go for 
IM therapy and keep the patient on follow-up.
Although GISTs exhibit a variable biological behaviour, 
10–30% of them are malignant.[13] This warrants 
requirement of a close follow-up based individually 
on tumour characters. The higher the risk, early is the 
chance of recurrence with median time of 2 years after 
surgery. Due to paucity of data, it is difficult to predict 
the malignant potential of prostatic EGISTs; however, 
it seems to be quite similar to that of intestinal GISTS. 
Tailored follow-up schedule using appropriate imaging 
is, therefore, required.
Conclusion
In this case report, we present one of the rarest prostatic 
malignancies. We recommend that:
1. EGIST should be considered in the differential 
diagnosis of the large firm to hard feeling prostates 
with normal PSA values.
2. Surgical resection should be considered in all cases 
where possible.
3. If not then, IM represents the alternative therapy and 
can also be used in combination with surgery.
4. Long-term follow-up is required in all cases.
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